Australian Abortion Pill Access Widens After Policy Change

Regulatory changes in 2023 allowed GPs, nurse practitioners, and midwives to prescribe the abortion pill MS-2 Step and removed pharmacist registration requirements. The Therapeutic Goods Administration lifted prescribing restrictions, allowing any GP to prescribe without specialist training. Administrative hurdles for prescribing and dispensing the medication were relaxed. By mid-2025, this policy shift had dramatically expanded access across the country.

Growth in pharmacy stocking and geographic reach

By mid-2025, 4,107 pharmacies in Australia were stocking MS-2 Step. Before the 2023 policy change, only 2,228 pharmacies stocked it. This represents a 48.6% increase. The geographic reach expanded significantly.

The number of Australian postcodes with a pharmacy stocking MS-2 Step rose from 915 to 1,292. Nearly half of all Australian postcodes now have access. Coverage improved in all areas.

Regional coverage in the most remote regions with 12 or more stocking pharmacies quadrupled, rising from 35 to 140. Increases occurred across all remoteness and socioeconomic categories, though they were greatest in major cities.

Researchers highlight equity and safety benefits

Study authors emphasize the improved access reduces travel burdens and supports disadvantaged women. Professor Kristina Edvardsson, lead author from La Trobe University’s School of Nursing and Midwifery, stated the change is critical for equity. "Australian women who need access to this medication can access it closer to home," she said. Removing unnecessary travel and stress is super important, especially for disadvantaged, rural, remote, and low-income women. Picking up the medication at a local pharmacy means getting care quicker.

Edvardsson also noted that improved access to MS-2 Step is safe and correlates with a decreased need for surgical abortion. She observed that in some European countries, medical abortion accounts for over 90% of abortions and Australia is heading in that direction. By 2020, women in regional and remote areas were nearly four times as likely to use medication abortion as procedural abortion.

Dr Anna Noonan, a postdoctoral research fellow and abortion researcher with the University of Technology Sydney, said the data should be an important signal to countries with restricted prescribing, such as the US. She argued that overregulation creates extra work for providers and does not serve people seeking care well. Encouraging a deregulated environment improves access, especially for people with fewer resources. Dr Noonan referenced 'invisible work' by local doctors and nurses who often contact pharmacies in advance to arrange stocking when becoming abortion providers in a community. Professor Danielle Mazza from Monash University is a study co-author.

Medication details and context of use

MS-2 Step, the only abortion pill available in Australia at the time of the study, consists of mifepristone and misoprostol. It is listed on the Pharmaceutical Benefits Scheme and can be taken up to 63 days of gestation. In February of this year, the TGA approved a generic alternative called Arzestra, which contains the same two medicines and has the same gestational limit.

The manufacturer, MS Health, has applied to extend the gestational limit for MS-2 Step from nine to ten weeks and to add it for miscarriage management up to 70 days. The Pharmaceutical Benefits Advisory Committee recommended the ten-week extension for the PBS listing in July and will consider the miscarriage listing in November.

Study methodology and timing

The research, published recently in JAMA Network Open, analyzed 24 months of pharmacy data before and after the 2023 TGA policy change. It found that by July 2025, there were 446 more pharmacies ordering MS-2 Step each month than expected if the old restrictions had remained. The study was led by researchers from La Trobe University.

By mid-2025, 4,107 pharmacies in Australia were stocking MS-2 Step.